Skip to main content
. 2011 Feb 15;2011:315418. doi: 10.1155/2011/315418

Figure 3.

Figure 3

Purkinje cell dendrite growth: calbindin fluorescence immunoreaction. Treatment with dose of 5 μg/g b.w. At PD11, compared to control rats (a), the dendrite of Purkinje cells appears less extended in the cisPt-treated rats (b); some tracts of lobules lack Purkinje cells (b). After treatment with PtAcacDMS, a less marked delay in branching is shown (c). At PD17, in respect of control features (d), the main dendrite branches of Purkinje cells are often thicken, distorted, or crowded (e, arrows), differently from PtAcacDMS-treated rats (f) showing a rich and fine Purkinje cell branching as in controls. Treatment with dose of 10 μg/g b.w. At PD17, the dendrites of Purkinje cells in cisPt-treated rats spread within the entire ML (g), but some branches are lacking (g, arrows). After PtAcacDMS (h), the labelling evidences similar features as in controls. Magnification: 40x.